Cargando…

DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2)

BACKGROUND: DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A formulation in clinical development. A phase 2 dose-ranging study identified an optimal dose and demonstrated efficacy with a median duration of 24 weeks. METHODS: In two phase 3, multicenter, randomized, double-b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carruthers, Jean D., Fagien, Steve, Joseph, John H., Humphrey, Shannon D., Biesman, Brian S., Gallagher, Conor J., Liu, Yan, Rubio, Roman G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Cosmetic: Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940025/ https://www.ncbi.nlm.nih.gov/pubmed/31609882 http://dx.doi.org/10.1097/PRS.0000000000006327

Ejemplares similares

Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials
por: Gallagher, Conor J., et al.
Publicado: (2023)

Efficacy and Safety of DaxibotulinumtoxinA for Injection in the Treatment of Glabellar Lines by Age and Race: Subgroup Analysis of the SAKURA Clinical Trials
por: Solish, Nowell, et al.
Publicado: (2022)

DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study
por: Fabi, Sabrina G., et al.
Publicado: (2021)

Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines
por: Humphrey, Shannon, et al.
Publicado: (2023)

A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines: A Focus on Safety From the SAKURA 3 Study
por: Green, Jeremy B., et al.
Publicado: (2021)

Prior Botulinum Toxin Treatment Does Not Impact Efficacy or Safety in Clinical Trials: Analysis of DaxibotulinumtoxinA for Injection in the SAKURA Program
por: Cohen, Joel L., et al.
Publicado: (2021)

Impact of DaxibotulinumtoxinA for Injection on Brow Position and Frontalis Muscle Activity Following Treatment of Glabellar Lines
por: Solish, Nowell, et al.
Publicado: (2022)

Impact of Glabellar Injection Technique With DaxibotulinumtoxinA for Injection on Brow Position
por: Bertucci, Vince, et al.
Publicado: (2022)

Progressive Improvement in Static Glabellar Lines After Repeated Treatment With DaxibotulinumtoxinA for Injection
por: Glogau, Richard, et al.
Publicado: (2021)

Sakura : tercinas del oriente remoto
por: Monterde, Francisco, 1894-1985
Publicado: (1963)

Bridging the Gap: Sustained Treatment Effect of Glabellar Lines With Twice-A-Year Treatment With DaxibotulinumtoxinA
por: Dover, Jeffrey S., et al.
Publicado: (2023)

Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A
por: Solish, Nowell, et al.
Publicado: (2021)

Long-term Efficacy of Satralizumab in AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar
por: Kleiter, Ingo, et al.
Publicado: (2022)

DAXI (DaxibotulinumtoxinA) – An Innovative Approach for Frown Lines
por: Mussarat, Abdullah, et al.
Publicado: (2023)

Treatment of Upper Facial Lines With DaxibotulinumtoxinA for Injection: Results From an Open-Label Phase 2 Study
por: Dover, Jeffrey S., et al.
Publicado: (2023)

Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose‐Escalation Multicenter Study
por: Jankovic, Joseph, et al.
Publicado: (2018)

Sakura-based activated carbon preparation and its performance in supercapacitor applications
por: Ma, Fei, et al.
Publicado: (2019)

The Crest Injection Technique for Glabellar Line Correction and the Paracentral Artery
por: Tansatit, Tanvaa, et al.
Publicado: (2021)

Central Forehead Ischemic Skin Injury following Glabellar Botulinum: A Paradigm Microshift?
por: Hynes, Stephanie D., et al.
Publicado: (2023)

The complete mitochondrial genome sequence of the sakura shrimp, Sergia lucens (Crustacea, Decapoda, Sergestidae)
por: Kawato, Satoshi, et al.
Publicado: (2018)

The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients
por: Kaufman-Janette, Joely, et al.
Publicado: (2021)

Safety, Pharmacodynamic Response, and Treatment Satisfaction With OnabotulinumtoxinA 40 U, 60 U, and 80 U in Subjects With Moderate to Severe Dynamic Glabellar Lines
por: Joseph, John H, et al.
Publicado: (2022)

Current use of direct oral anticoagulants for atrial fibrillation in Japan: Findings from the SAKURA AF Registry
por: Okumura, Yasuo, et al.
Publicado: (2017)

IncobotulinumtoxinA for Glabellar Frown Lines in Chinese Subjects: A Randomized, Double-blind, Active-Controlled Phase-3 Study
por: Wu, Yan, et al.
Publicado: (2023)

A Prospective, Multicenter, Single-Blind, Randomized, Controlled Study of VYC-15L, a Hyaluronic Acid Filler, in Adults for Correction of Infraorbital Hollowing
por: Fabi, Sabrina, et al.
Publicado: (2021)

PrabotulinumtoxinA vs OnabotulinumtoxinA for the Treatment of Adult Males With Moderate to Severe Glabellar Lines: Post-hoc Analyses of the Phase III Clinical Study Data
por: Solish, Nowell, et al.
Publicado: (2022)

Dermal Micro-coring for the Treatment of Moderate to Severe Facial Wrinkles
por: Gfrerer, Lisa, et al.
Publicado: (2022)

Long-term Efficacy and Safety of Liquid AbobotulinumtoxinA Formulation for Moderate-to-Severe Glabellar Lines: A Phase III, Double-Blind, Randomized, Placebo-Controlled and Open-Label Study
por: Kestemont, Philippe, et al.
Publicado: (2021)

The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients
por: Lorenc, Z Paul, et al.
Publicado: (2021)

Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines
por: Ascher, Benjamin, et al.
Publicado: (2019)

Repeated OnabotulinumtoxinA Treatment of Glabellar Lines at Rest Over Three Treatment Cycles
por: Carruthers, Alastair, et al.
Publicado: (2016)

Study of assessment of knowledge and understanding for coping with sick days among patients with diabetes in community pharmacy: a cluster randomized controlled trial (SAKURA trial)
por: Kado, Keisuke, et al.
Publicado: (2023)

Safety and Effectiveness of Repeat Treatment With VYC-15L for Lip and Perioral Enhancement: Results From a Prospective Multicenter Study
por: Rivkin, Alexander, et al.
Publicado: (2019)

Submental Area Treatment with ATX-101: Relationship of Mechanism of Action, Tissue Response, and Efficacy
por: Humphrey, Shannon, et al.
Publicado: (2022)

A Multicenter Noninferiority Study Comparing Safety and Effectiveness of Hyaluronic Acid Fillers for Correction of Nasolabial Folds in Chinese Subjects
por: Li, Wenzhi, et al.
Publicado: (2023)

Facial Skin Revitalization with Cohesive Polydensified Matrix-HA20G: Results from a Randomized Multicenter Clinical Study
por: Kerscher, Martina, et al.
Publicado: (2021)

Efficacy and Safety of ATX-101 by Treatment Session: Pooled Analysis of Data From the Phase 3 REFINE Trials
por: Dayan, Steven H, et al.
Publicado: (2018)

Intraoperative Interpectoral and Subserratus Nerve Blocks in Breast Augmentation Surgery
por: Lee, Mark A., et al.
Publicado: (2022)

Comparison of the Antialbuminuric Effects of L-/N-type and L-type Calcium Channel Blockers in Hypertensive Patients with Diabetes and Microalbuminuria: The Study of Assessment for Kidney Function by Urinary Microalbumin in Randomized (SAKURA) Trial
por: Ando, Katsuayuki, et al.
Publicado: (2013)

Development and Validation of a Photographic Scale for Assessment of Lip Fullness
por: Werschler, W. Philip, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8s4t08ukkdr4riu32ul2a3ae2o